Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.72 |
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 9/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926416 | 0.90 | MAPT (0.72) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4926128 | 0.89 | TP53 (0.79) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL31615154 | 0.83 | MAPT (0.84) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4924582 | 0.81 | TP53 (0.59) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6206370 | 0.81 | KDM4E (0.73) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4923684 | 0.80 | LMNA (0.75) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4930831 | 0.80 | LMNA (0.74) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL10016528 | 0.79 | RAB9A (1.00) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4924472 | 0.77 | TP53 (0.53) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4923741 | 0.76 | TP53 (0.52) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | claimed |
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096868-A1 | 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors | MAP3K1, MAP4K2, MAP4K5 | MAPT 1638/4885NPC1 1579/4885RAB9A 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.